Rockwell Medical, INC 10-Q quarterly reports

Rockwell Medical's Q2 2026 Form 10-Q filing reveals a slight increase in net sales and improved gross profit, but continued net losses, with management highlighting efforts towards sustainable profitability and potential capital raises.

Rockwell Medical, Inc. reported a net sales decrease of 8% for the first quarter of 2026 compared to the prior year, primarily driven by reduced sales to DaVita.

Rockwell Medical experienced a significant drop in net sales and shifted to a net loss for Q3 and the first nine months of 2025, primarily due to reduced DaVita purchases.

Rockwell Medical, Inc. reported a significant decline in net sales and a widened net loss for the second quarter and first half of 2025, primarily due to a major customer transitioning to a new supplier.

Rockwell Medical's Q1 2025 revenue decreased due to a major customer transitioning to another supplier, despite price adjustments and new distribution agreements.

Rockwell Medical's Q3 2024 results show a significant increase in revenue and a return to profitability, driven by strong product sales and a large premium-priced order.

Rockwell Medical saw a significant increase in net sales and gross profit in the second quarter of 2024, driven by new customer acquisitions and price increases.

Rockwell Medical's first quarter 2024 results show a 15% increase in net sales compared to the same period last year, driven by new customer acquisitions and price increases.